Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Zydus Has Expansion Plans In Japan After Nippon Acquisition

This article was originally published in PharmAsia News

Executive Summary

Zydus Cadila, an Indian pharmaceutical company, plans to release its first new generic drug in 10 years and expand its portfolio of other generics in Japan. Zydus acquired the Japanese generics maker, Nippon Universal Pharmaceutical, last April. The new drug launched by Zydus is a generic of UCB Japan's Zyrtec (cetirizine hydrochloride) for treating allergies. The Nippon arm plans to acquire the sales rights for nine other generics drugs to add to its portfolio of six, and increase its sales representative staff from 11 to 25 by next October. (Click here for more - may require a subscription
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC067800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel